Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)
Medical Services Advisory Committee
Record ID 32015000583
English
Authors' recommendations:
ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1250.1-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Protein Kinase Inhibitors
- Anaplastic Lymphoma Kinase
- Crizotinib
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
<p>Medical Services Advisory Committee (MSAC)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.